Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Butylscopolamine bromide
Drug ID BADD_D00326
Description Butylscopolamine is a peripherally acting antimuscarinic, anticholinergic agent. It is used to treat pain and discomfort caused by abdominal cramps, menstrual cramps, or other spasmodic activity in the digestive system. It is also effective at preventing bladder spasms. It is not a pain medication in the normal sense, since it does not directly affect pain, but rather works to prevent painful cramps and spasms from occurring. It is on the WHO Model List of Essential Medicines, the most important medications needed in a basic health system.
Indications and Usage Used to treat abdmoninal cramping and pain [FDA Label].
Marketing Status approved; investigational; vet_approved
ATC Code A03BB01
DrugBank ID DB09300
KEGG ID D01451
MeSH ID D002086
PubChem ID 656587
TTD Drug ID D05EMG
NDC Product Code 12714-011; 51927-0206
UNII 0GH9JX37C8
Synonyms Butylscopolammonium Bromide | Bromide, Butylscopolammonium | Scopolaminebutylbromide | Hyoscine N-Butylbromide | Hyoscine N Butylbromide | N-Butylbromide, Hyoscine | N-Butylscopolammonium Bromide | Bromide, N-Butylscopolammonium | N Butylscopolammonium Bromide | Butylscopolamine | Hyoscinbutylbromide | Scopolan | Buscopan | Buscapine | Buscolysin
Chemical Information
Molecular Formula C21H30BrNO4
CAS Registry Number 149-64-4
SMILES CCCC[N+]1(C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4)C.[Br-]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Accommodation disorder06.02.04.001--Not Available
Anaphylactic shock24.06.02.004; 10.01.07.002--Not Available
Anaphylactoid reaction24.06.03.007; 10.01.07.003--Not Available
Angioedema22.04.02.008; 23.04.01.001; 10.01.05.009--Not Available
Death08.04.01.001--
Dermatitis23.03.04.002--Not Available
Diarrhoea07.02.01.001--
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.003--
Drug eruption23.03.05.001; 10.01.01.005; 08.01.06.015--Not Available
Dry mouth07.06.01.002--
Dyshidrotic eczema23.03.04.034--Not Available
Dyspnoea02.11.05.003; 22.02.01.004--
Erythema23.03.06.001--Not Available
Eye disorder06.08.03.001--Not Available
Flushing24.03.01.002; 23.06.05.003; 08.01.03.025--
Gastrointestinal disorder07.11.01.001--Not Available
Glaucoma06.03.01.002--
Hypersensitivity10.01.03.003--
Hypotension24.06.03.002--
Immune system disorder10.02.01.001--Not Available
Intraocular pressure increased13.07.04.002--Not Available
Mydriasis17.02.11.003; 06.05.03.004--Not Available
Nausea07.01.07.001--
Pruritus23.03.12.001--
Rash23.03.13.001--Not Available
Retinal pigmentation06.09.03.008--Not Available
Shock24.06.02.002--Not Available
Skin disorder23.03.03.007--Not Available
Tachycardia02.03.02.007--Not Available
Urethral disorder20.07.01.002--Not Available
The 1th Page    1 2    Next   Last    Total 2 Pages